Table 2:

Characteristics of Patients Achieving HBsAg Loss

ID	Treatment	Age in years	Sex	Race	HBeAg at Start of Treatment	Geno type	HBV DNA log10 IU/mL	qHBsAg log10 IU/mL	qHBeAg log10 IU/mL	ALT U/L	ISHAK	Week of HBsAg Loss	Status at time of HBsAg Loss
A	TDF alone	66·7	F	White	Positive	A2	8·6	5·1	3·6	129	2	71	On treatment
B	TDF alone	45·9	M	Black	Positive	A2	7·3	4·1	2·2	94	3	217	Off treatment
C	TDF alone	41·2	M	White	Positive	A2	8·6	5·0	3·4	92	6	197	On treatment
D	TDF alone	37·5	M	White	Positive	A2	8·8	4·9	3·2	66	2	217	Off treatment
E	TDF+PegIFN	37·2	F	Asian	Negative	C	4·2	2·3	N/A	91	0	71	On treatment
F	TDF+PegIFN	53·2	M	White	Positive	A2	8·4	5·2	3·4	88	4	25	On treatment
G	TDF+PegIFN	60·0	M	White	Positive	A2	8·5	5·1	3·2	66	2	36	On treatment
H	TDF+PegIFN	53·3	F	Black	Positive	A2	8·4	4·8	3·5	54	5	25	On treatment
I	TDF+PegIFN	34·4	F	Asian	Positive	B	8·1	4·5	3·3	56	1	121	On treatment

ALT, alanine aminotransferase; HAI, hepatitis activity index; PegIFN, peginterferon; TDF, tenofovir disoproxil fumarate